home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407f.zip
/
M9471092.TXT
< prev
Wrap
Text File
|
1994-08-09
|
3KB
|
42 lines
Document 1092
DOCN M9471092
TI Pilot study-photodynamic therapy (PDT) for treatment of AIDS-associated
Kaposi's sarcoma (AIDS/KS) (Meeting abstract).
DT 9409
AU Bernstein ZP; Wilson D; Mang TS; Dept. of Medicine and Radiation
Medicine, Roswell Park Cancer; Inst.
SO Proc Annu Meet Am Soc Clin Oncol; 13:A6 1994. Unique Identifier :
AIDSLINE ICDB/94600003
AB Lesions of AIDS/KS are often painful and cosmetically disfiguring.
Treatment options are often limited by the patient's poor immune status.
In an attempt to offer palliative therapy which would not further
compromise the patient's immune system, we initiated a pilot study of
PDT in AIDS/KS. The therapy is predicated on the activation by light of
a photosensitizing drug (Photofrin) which preferentially accumulates in
malignant tissues such as KS, after administration by intravenous
injection. All entrants received 1.0 mg/kg of photofrin by iv injection
48 hr prior to exposure to 100-200 J/cm2 of 630 nm light. Ten patients
with cutaneous AIDS/KS have been entered to date. Two had oral lesions
as well. The number of lesions treated per individual ranged from 2 to
20 with three individuals having greater than 15 lesions treated. Two
patients expired within one month of treatment and were thus deemed
nonresponders. The mean time to re-epithelization of treated areas was
20 days. The one surviving individual with oral lesions had a response
duration of 120 days. Of the remaining six patients, five had a CR of
all lesions for a minimum period of 60 days. The remaining patient had a
mixed response and was retreated to a total CR for a period of 80 days.
There have been no grade 3 toxicities experienced to date and there were
no detectable statistically significant changes in CD4 cell numbers
during the period of observation (mean 90 days). The data suggests that
PDT offers a safe, tolerable, cosmetically acceptable palliative therapy
of cutaneous KS lesions without detriment to the patient's immune
system.
DE Acquired Immunodeficiency Syndrome/*DRUG THERAPY Follow-Up Studies
*Hematoporphyrin Photoradiation Human Injections, Intravenous Mouth
Neoplasms/DRUG THERAPY Palliative Treatment Pilot Projects Sarcoma,
Kaposi's/*DRUG THERAPY Skin Neoplasms/*DRUG THERAPY MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).